While the human immunodeficiency virus (HIV) pandemic fuels tuberculosis (TB) outbreaks, it does not drive the development and transmission of multidrug-resistance in TB patients as previously suspected, according to a study published in eLife.
09 August 2016 | EurekAlert (press release)
These FAQs address key points regarding the implementation of the WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, in TB and TB/HIV programmes.
15 June 2016 | World Health Organization
The ground-breaking publication of Lord Jim O'Neill's global Review on Antimicrobial Resistance (AMR) is the wake-up call the world desperately needs. Have no doubts: the 'superbugs' that develop antimicrobial resistance are a threat of immense proportions and have a potential impact of 10 million deaths a year by 2050 as antibiotic efficacy dwindles.
20 May 2016 | Huffington Post UK
New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
12 May 2016 | World Health Organization
Stage 2 of the trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.
18 April 2016 | International Union Against Tuberculosis and Lung Disease
Paul Farmer first saw multidrug-resistant tuberculosis in the early 1990s in Haiti, from where he smuggled a patient’s sputum sample to test for drug resistance in Boston. Months later, Partners in Health co-founder Dr. Jim Kim with other colleagues discovered a cluster of fifty MDR-TB patients in a squatter settlement of 100,000 in Lima, Peru. That’s when they started to talk to the world about the emergence of MDR-TB.
24 March 2016 | Science Speaks
Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).
24 March 2016 | Médecins Sans Frontières
At last week’s launch of the National Action Plan for Combating Multidrug-Resistant Tuberculosis, the U.S. Agency for International Development announced expanded partnerships with Janssen, the maker of bedaquiline, the first tuberculosis drug to be produced since the 1950s, and Cepheid, maker of the GeneXpert rapid diagnostic test for drug-resistant tuberculosis.
13 January 2016 | Science Speaks
A 2012 article in the Journal of Tuberculosis and Lung Disease noted that the powerfully negative connotation of words such as “defaulter” and “suspect” placed blame for the disease and responsibility for adverse treatment outcomes on just one side: people with TB. Is it any wonder that patients fail to complete their treatment or don’t return for checkups if they are made to feel guilty?
12 January 2016 | Devex
Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB.
11 January 2016 | Treatment Action Group